Meijer Leverages NovoCare to Expand GLP-1 Access, Signals Retail Pharmacy Shift
Event summary
- Meijer is offering Wegovy® and Ozempic® (semaglutide) at reduced prices through the NovoCare savings program.
- Introductory pricing includes $199/month for the lowest doses for the first two months, followed by $349/month (highest dose $499/month).
- Meijer is also offering the newly FDA-approved oral Wegovy® pill with out-of-pocket options starting at $149/month and co-pays as low as $25.
- The program is available through March 31, 2026, and excludes customers with government-funded insurance.
The big picture
Meijer's move signals a potential shift in how retailers approach pharmaceutical pricing and access, leveraging manufacturer-sponsored programs to attract and retain customers. This strategy could be a response to increasing consumer demand and pressure on healthcare costs, particularly as GLP-1 medications gain wider adoption. The partnership also highlights the growing importance of value-added services, such as nutritional counseling, in the retail pharmacy model.
What we're watching
- Competitive Response
- Other regional and national retailers will likely evaluate similar partnerships to capture market share in the rapidly growing GLP-1 medication space, potentially triggering a price war.
- Program Sustainability
- The long-term viability of the NovoCare program and Meijer's ability to absorb the initial price discounts will depend on Novo Nordisk’s continued participation and willingness to share savings.
- Nutritional Services
- Meijer's expansion of Nutrition by Meijer services suggests a broader strategy to capture ancillary revenue and build customer loyalty around GLP-1 therapy, which could be replicated by competitors.
Related topics